JPRN-UMIN000013301已完成2 期
Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic cancer - modified FOLFIRINOX
Cancer Institute Hospital0 个研究点目标入组 65 人开始时间: 2014年2月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Prior radiotherapy or chemotherapy Homotype of UGT1A1 genotype including *28/*28, *6/*6 and*6/*28 Evident pleural effusion, ascites, pericardial effusion or peritoneal metastasis on CT before enrollment Pulmonary fibrosis or interstitial pneumonia Watery stool within 3 days before enrollment Uncontrolled diabetes mellitus Any serious complication
研究者
相似试验
已完成
2 期
Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000015376Gifu University Hospital28
已完成
2 期
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2)locally advanced pancreatic cancerJPRN-UMIN000023143Japan Clinical Oncology Group (JCOG)124
进行中（未招募）
不适用
A phase II study of modified FOLFIRINOX(5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for advanced biliary tract cancer after gemcitabine based chemotherapy failureKCT0004433Gyeongsang National University Hospital34
招募中
不适用
A trial of Neoadjuvant modified FOLFIRINOX chemotherapy for resectable pancreatic adenocarcinomaNeoplasmsKCT0004421Yonsei University Health System, Severance Hospital27
未知
2 期
A phase 2 trial of FOLFIRINOX in patients with previously untreated metastatic pancreatic cancerpreviously untreated pancreatic cancerJPRN-jRCT2080221426Yakult Honsha Co.,Ltd.35